cladribine / Generic mfg. - LARVOL DELTA

Tagraxofusp and low-intensity chemotherapy for the treatment of CD123-positive relapsed or refractory Acute Myeloid Leukemia (ASH 2025) - P1/2 | "Background and Significance: The combination of venetoclax and a hypomethylating agent (Ven/HMA) is the standard frontline (1L) therapy for patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy (IC)...Cladribine (CLAD) with low-dose cytaratbine (LDAC) has previously been shown to be well-tolerated and effective in IC-ineligible patients with newly diagnosed AML...The study began enrolling patients in January 2025 and is actively recruiting. Clinical Trial Registration NCT06561152"

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • BCL2 • CD123 • IL3RA

Utilization patterns of venetoclax-based regimens for AML in a community based setting & representative populational analyses (ASH 2025) - "In first line setting, 22 patients (52.3%) received Venetoclax with azacitidine, 17 patients 40.1% received decitabine, 2 patients (4.8%) with cladribine and cytarabine, and 2 patients (4.8%) received Venetoclax alone...6 patients (40%) received azacitidine with venetcloax, 6 patients (40%) received decitabine, 1 patient (6.7%) received cytarabine, 1 patient (6.7%) received enasidenib, and one patient (6.7%) received nelarabine, cyclophosphamide, and cytarabine... The median age at diagnosis was 64 years (range 21-86). 47% patients were female gender. 24.5% of patients were Black or African-American, 71.4% were White, 1% were Asian, and 3.1% were more than one race."

Clinical • Acute Myelogenous Leukemia • Febrile Neutropenia • Hepatology • Liver Failure • Neutropenia • Renal Disease • CEBPA • DDX41 • NPM1 • TP53

Real-world AML survival paradox: Early escalation vs. sustained remission (ASH 2025) - "Patients were stratified into two cohorts: Cohort A (early escalation, n=1,460), comprising patients who received either second-line chemotherapy (including fludarabine, cladribine, gilteritinib, enasidinib, revumenib, olutasidenib, etoposide, or clofarabine) or hematopoietic stem cell transplant (HSCT) as salvage therapy within 6 months of completing initial therapy; and Cohort B (no escalation, n=10,540), consisting of patients who received no additional therapy during this same period. Our findings highlight the complex interplay between disease biology and treatment interventions: achieving MRD-negativity remains critical, but when MRD-positivity occurs, subsequent treatment decisions based on disease genetics prove critical. Prospective studies incorporating molecular MRD monitoring are needed to confirm these findings and further optimize post-remission therapy approaches."

Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia

Good report of secondary allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed Acute Myeloid Leukemia (ASH 2025) - "Thirty-five patients received a conditioning regimen primarily consisting of TBI plus fludarabine/cladribine, while 8 patients received a regimen primarily consisting of BU plus fludarabine/cladribine. Achieving CR prior to secondary HSCT is associated with higher post-transplantation OS rates. In cases where CR cannot be achieved, salvage secondary HSCT is also a viable option."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • CNS Disorders • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Transplantation

FluMel100 with post-transplant cyclophosphamide: A safe and effective regimen for patients aged ≥75 years with MDS and AML (ASH 2025) - "Many published studies in older adults have often utilized non-myeloablative and reduced intensity conditioning regimens, including fludarabine/total body irradiation, fludarabine/melphalan (FluMel) and fludarabine/busulfan combined with varied graft versus host disease (GVHD) prophylaxis approaches...They underwent re-induction therapy with cladribine, low dose cytarabine and venetoclax, achieving a complete remission, followed by donor leukocyte infusion (DLI)... Eight patients were included: seven with AML (n=7) and one had MDS (n=1), Kanofsky Performance Status range 80-90%, HCT-CI (Comorbidity Index) range 0-7. All patients received peripheral blood stem cell (PBSC) grafts from human leukocyte antigen (HLA) matched unrelated donors (MUD). PT-Cy dose was 80 mg/kg (n= 7) and 50mg/kg (n= 1)."

Clinical • Post-transplantation • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Geriatric Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Transplantation • CD33 • HLA-DPB1

Systemic mastocytosis with associated lymphoid neoplasms (SM-ALN): A distinct subset with indolent clinical course and favorable outcomes (ASH 2025) - "SM management was divided into two categories: (1) Conservative approach, including observation alone in 4 patients (22%) and symptomatic therapies such as antihistamines or leukotriene inhibitors in 7 (39%); and (2) Cytoreductive treatments, comprising avapritinib in 5 patients (28%), cladribine in 1 (6%), and imatinib in 1 (6%). Management of lymphoid neoplasms included intensive regimens such as R-CHOP and hyper-CVAD for high-grade subtypes (e.g., DLBCL and T-ALL), while indolent forms (e.g., CLL and follicular lymphoma) were treated with bendamustine-rituximab or observation depending on disease burden... SM-ALN is a rare but distinct SM subtype characterized by indolent behavior, favorable treatment responses, and prolonged survival. Recognition of this subset is critical to avoid over-treatment and to guide risk-adapted management strategies."

Clinical • Acute Lymphocytic Leukemia • Aggressive Systemic Mastocytosis • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Dermatology • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Pruritus • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • ASXL1 • CCND3 • CXCR4 • DNMT3A • IDH1 • JAK2 • KIT • MYD88 • NOTCH2 • RUNX1 • SF3B1 • SRSF2 • TET2 • TP53

Rapid transformation from JAK2-positive PMF to acute leukemia: Therapeutic challenges and rare DIC in an aggressive disease course (ASH 2025) - "Emergency leukapheresis and hydroxyurea were started for cytoreduction...Treatment options considered included combination chemotherapy with low-dose cytarabine (Ara-C), cladribine, and venetoclax, versus a palliative approach due to the patient's declining functional status and aggressive disease biology... This case underscores the clinical significance and poor prognosis associated with leukemic transformation of JAK2-positive PMF, particularly in the presence of high-risk mutations such as RUNX1 and TP53. These mutations not only predict an aggressive clinical course but also portend resistance to conventional hypomethylating agents. While decitabine provided initial stabilization, the early relapse highlights the limitations of current therapies in such molecularly adverse settings."

Acute Myelogenous Leukemia • Back Pain • Fibrosis • Hematological Malignancies • Immunology • Leukemia • Metabolic Disorders • Musculoskeletal Pain • Myelofibrosis • Myeloproliferative Neoplasm • Nephrology • Renal Disease • Thrombocytopenia • ABL1 • BCR • JAK2 • RUNX1 • TP53

Impact of induction regimen and co-mutations on outcomes in AML with myelodysplasia-related changes (ASH 2025) - "Induction therapies were grouped into 4:1- Cytarabine plus anthracycline (7+3) with or without targeted therapy; 2-Hypomethylating agent (HMA) plus venetoclax with or without targeted therapy; 3-Cladribine- or fludarabine-based regimens; 4-Low-dose cytarabine with or without HMA or other targeted therapies... Epigenetic mutations are highly enriched in AML-MRC. CLIA-Ven achieved the highest CR/CRi rates, followed by Vyxeos, 7+3, and HMA-Ven. However, after adjusting for age, gender, and performance status, no differences were observed in RFS or OS among 7+3, HMA-Ven, or Vyxeos."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • ASXL1 • BCOR • CALR • CEBPA • DNMT3A • FLT3 • IDH1 • IDH2 • KRAS • NPM1 • NRAS • PTPN11 • RUNX1 • SF3B1 • SRSF2 • TET2 • TP53 • U2AF1

Impact of NPM1 co-mutation on outcomes in RAS-mutated Acute Myeloid Leukemia (ASH 2025) - "RAS mutations in AML have been recently shown to impart an intermediate prognostic risk when treated with hypomethylating agents (HMA) + venetoclax and may benefit from high-dose cytarabine consolidation in pts treated with intensive chemotherapy (IC)...Comparison within different treatment groups shows that pts treated with low-intensity chemotherapy (Low-IC) [Cladribine+LDAC or HMA] without Venetoclax (Ven) had a median OS of 17.9 months (CI 3.8–46.6) vs. 7.2 months (CI 4.8–10.02; p = 0.04) for RAS -mut/ NPM1 -mut vs. RAS -mut/ NPM1 -wt, respectively... The prognostic impact of RAS mutations in AML is modified in the setting of NPM 1 co-mutations. Pts with RAS -mutated AML without co-occurring NPM1 mutations had significantly inferior OS and EFS than those with RAS- mut/ NPM1- mut. Low-IC and IC alone showed a clear survival benefit for RAS -mut/ NPM1 -mut compared to RAS -mut/ NPM1 -wt."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • HRAS • KMT2A • KRAS • NPM1 • NRAS • RAS

Real-world comprehensive single-institution analysis of AML with TP53-mutation (ASH 2025) - "For younger/fit patients (pts), intensive induction therapy is often considered while hypomethylating agents (HMA's) with or without venetoclax remains the standard for older/unfit pts...Frontline treatment regimens were stratified by intensive induction therapy (IIT) including 7+3 with or without cladribine, CPX-351, or clofarabine, cytarabine, G-CSF (CLAG) with or without investigational therapies...AlloSCT was associated with improved OS outcomes, although a limited proportion of patients were able to proceed to alloSCT as consistent with previously published data. These findings underscore the urgent need to develop novel therapeutic strategies, prioritize clinical trial options, and optimize alloSCT selection and timing for patients with TP53m AML."

Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • TP53

Prospective clinical study on the efficacy and safety of the DCIA±X regimen in treating relapsed/refractory acute myeloid leukemia (ASH 2025) - "The DCIA±X regimen—combining decitabine, cladribine, idarubicin, cytarabine, and optional targeted agents (X)—leverages synergistic mechanisms to overcome chemoresistance. This novel reinduction regimen demonstrated robust activity and acceptable toxicity in treating R/R AML patients, achieving high CR/CRi and ORR rates, facilitating successful bridge to transplant in most responders, and promising 1-year RFS and OS."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia

High-intensity purine analogue-based therapy for refractory/relapsed Acute Myeloid Leukemia (RR-AML): A single-institution experience (ASH 2025) - "For medically fit patients, high-intensity salvage regimens such as CLAG or FLAG-IDA incorporate purine analogues (cladribine or fludarabine) with high-dose cytarabine and granulocyte colony-stimulating factor (G-CSF), achieving complete remission (CR) rates between 30% and 60% in the relapsed setting...Five patients (29%) received FLAG-IDA (2 of them received a concomitant FLT3 inhibitor: midostaurin and quizartinib), 7 patients (41%) received FLAG-IDA + venetoclax, 4 (24%) received CLAG-IDA + Venetoclax, and 1 patient (6%) received CLAG + VEN... Our single-institution experience demonstrates that high-intensity purine analogue-based therapy is safe and active in patients with RR-AML and can achieve meaningful remission rates in a heavily pretreated, predominantly adverse risk population. These outcomes compare favorably to historic expectations and support the use of purine analogue regimens as an effective salvage strategy. Prospective studies and continued real-world..."

Clinical • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • FLT3 • IDH1 • TP53

Cladribine-based regimens for Relapsed/Refractory Acute Myeloid Leukemia – a real-world multicenter retrospective study (ASH 2025) - "The majority of patients were priorly exposed to venetoclax and azacitidine (87% and 77%, respectively) and 60% had prior allogeneic hematopoietic stem cell transplantation (AHSCT)...The majority (83%) received Clad-LDAC-Ven triplet, one patient received navitoclax as well, one patient received Clad-Ven with decitabine and three patients received Clad-Ven with intermediate-dose cytarabine... This real-world analysis, conducted in a predominantly elderly with R/R AML, suggests that the Clad-Ven-based regimen may offer transient disease control, primarily in patients who subsequently received either HCT or donor lymphocyte infusions. While the regimen may serve as a potential bridging strategy, its overall efficacy appears limited in the absence of consolidative immunotherapeutic interventions and is associated with significant infectious toxicity."

IO biomarker • Real-world • Real-world evidence • Retrospective data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Neutropenia • Septic Shock • IDH1 • MECOM • NPM1 • TP53

Efficacy and Safety of cladribine combined with cytarabine and G-CSF in Eliminating Measurable Residual disease for Core-binding factor acute myeloid leukemia: A retrospective, single-arm, multicenter study (ASH 2025) - "Treatment-related deaths were not observed. Conclusions CLAG regimen might be an effective and well tolerated regimen for eliminating MRD in CBF-AML ."

Residual disease • Retrospective data • Acute Myelogenous Leukemia • Infectious Disease • Neutropenia • Pneumonia • Respiratory Diseases • Thrombocytopenia • RUNX1 • RUNX1T1

Clia plus venetoclax for AML: Feasibility and efficacy in a hybrid community setting (ASH 2025) - "Induction consisted of cladribine 5 mg/m 2 IV (days 1-5), cytarabine 1-1.5 g/m 2 IV (days 1-5), and idarubicin 10 mg/m 2 IV (days 1-3), and venetoclax 400 mg PO (days 2-8; dose-adjusted for azole use). CLIA-VEN was well tolerated and yielded high MRD-negative remission rates in a hybrid community oncology setting, with encouraging survival outcomes and successful bridging to alloSCT. The absence of TRM and the high proportion of patients achieving MRD negativity mirror outcomes reported in academic phase 2 studies, suggesting that such results are achievable outside specialized tertiary centers. These findings underscore the feasibility of implementing intensive VEN-based regimens in hybrid community practices, where logistical constraints and patient demographics may differ from those in trial populations."

Clinical • Acute Myelogenous Leukemia • Febrile Neutropenia • Infectious Disease • Myelodysplastic Syndrome • Neutropenia • DNMT3A • FLT3 • IDH1 • KMT2A • NPM1

Efficacy and safety of CAV (cladribine, cytarabine and venetoclax) regimen in patients with newly diagnosed Acute Myeloid Leukemia (ASH 2025) - P4 | "In addition to the aforementioned 2 patients who died of cerebral thrombosis during induction chemotherapy, there was also 1 case with cardiac insufficiency before chemotherapy and later died of cardiac insufficiency, and the rest of the patients survived disease-free until the end of follow-up. In conclusion, CAV regimen has achieved a very high CR rate in induction therapy for newly diagnosed AML, even in adverse subgroup, platelets and neutrophils recover quickly, and there is no occurrence of serious infection, but our sample number is small, and then the sample size will be further expanded to confirm the efficacy of CAV regimen in the adverse subgroup, laying the foundation for the promotion of clinical induction chemotherapy for newly diagnosed AML."

Clinical • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Bone Marrow Transplantation • Central Nervous System Leukemia • Chronic Myeloid Leukemia • Congestive Heart Failure • Heart Failure • Hematological Disorders • Hematological Malignancies • Infectious Disease • Ischemic stroke • Leukemia • Myelodysplastic Syndrome • Pneumonia • Respiratory Diseases • Thrombosis • ASXL1 • BCOR • CBFB • CEBPA • ETV6 • FLT3 • IDH2 • KIT • KRAS • NF1 • NPM1 • NRAS • PTPN11 • RUNX1 • STAG2 • TP53 • U2AF1

Combination of mitoxantrone hydrochloride liposome with CLAG regimen in patients with relapsed or refractory Acute Myeloid Leukemia: A prospective, single-arm study (ASH 2025) - P4 | "The CLAG ± M/I regimen [cladribine, cytarabine, granulocyte colony-stimulating factor (G-CSF) ± mitoxantrone or idarubicin] is a common utilized chemotherapy regimen. Lipo-MIT combined with CLAG regimen showed a promising efficacy and manageable safety in R/R AML. The favorable post-transplant survival suggests this regimen is effective to bridge R/R AML patients to HSCT. The trial is still ongoing."

Clinical • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Bone Marrow Transplantation • Colorectal Cancer • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Leukopenia • Neutropenia • Thrombocytopenia • ASXL1 • CEBPA • FLT3 • TP53 • U2AF1

Very low risk for secondary malignancies with btkis in Waldenström macroglobulinemia: A retrospective real-world multicenter study. (ASH 2025) - "However, real-world data on the incidence and characteristics of SPMs in WM are scarce.The aim of our study was to evaluate, in a real-life multicenter cohort, the incidence, type, and riskfactors associated with SPMs in WM patients treated with various therapeutic strategies, includingbendamustine-rituximab (BR), dexamethasone-rituximab-cyclophosphamide (DRC), otherchemoimmunotherapy (CIT) schemes including fludarabine or chlorambucil or cladribine, BTK inhibitors(BTKis), and rituximab or steroids.This retrospective analysis included 489 patients diagnosed with WM and treated across 14 Italianhematology centers from 2008 to 2024. Although retrospective, our findings support the integration of BTKi early intreatment algorithms to reduce SPM risk. Prospective registries, longer-term follow-up and comparisonwith other casistics will be critical to define cumulative risk, especially as next-generation BTKi showpromising results with even better selectivity and tolerability."

Real-world • Real-world evidence • Retrospective data • Hematological Malignancies • Lymphoma • Lymphoplasmacytic Lymphoma • Oncology • Waldenstrom Macroglobulinemia • MYD88

Efficacy and safety of FLAG and CLAG regimens (Replacing Cyclophosphamide) in conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory malignant hematologic diseases (ASH 2025) - "The conditioningregimens consisted of: total body irradiation (TBI, total 8-10 Gy) or busulfan (3.2mg/kg, once daily for 3days), G-CSF (5ug/kg once daily for 5 days), fludarabine (30 mg/m² once daily for 5 days) or cladribine(5mg/m2 once daily for 5 days), cytarabine (1 g/m² once daily for 5 days), optional etoposide (200 mg/m²once daily for 3 days) and antithymocyte globulin (ATG). Cyclosporine, mycophenolate mofetil and short-term methotrexate were employed for graft-versus-host disease (GVHD) prophylaxis... Our cohort comprised heavily pretreated patients, among whom a substantial proportionhad undergone second or salvage transplantation. Notably, the 2-year LFS and OS still reached to 47.3%and 62.5%, respectively, accompanied by a relatively low NRM. These findings thus suggest thatsubstituting CTX with FLAG/CLAG regimens in the conditioning therapy for allo-HSCT is both effective andsafe for patients with r/r malignant hematologic diseases."

Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Myelodysplastic Syndrome • Transplantation

Phase 2 trial of encorafenib plus binimetinib for patients with BRAF V600 mutated relapsed/refractory hairy cell leukemia (ASH 2025) - "Background : Hairy cell leukemia (HCL) is an indolent B-cell leukemia characterized by durable completeremissions to purine analogs cladribine or pentostatin, but repeated relapses and cumulative toxicity torepeated purine analog courses...Vemurafenib was combined with rituximab,achieving 57% MRD-free CRs... Encorafenib-binimetinib is highly effective in relapsed/refractory HCL and was well toleratedwhen dose reductions occurred as needed. Compared to dabrafenib-trametinib, the lower incidence offever (11% vs 58%, p<0.0001) is a major advantage. The CR rate of 93% without rituximab isunprecedented for BRAF inhibition in HCL."

Clinical • P2 data • Hairy Cell Leukemia • Hematological Malignancies • Leukemia • Melanoma • Musculoskeletal Pain • Pancreatitis • Retinal Disorders • Solid Tumor • BRAF

Venetoclax, cladribine plus low-dose cytarabine for relapsed/refractory Acute Myeloid Leukemia: A multicenter, randomized phase II Study (ASH 2025) - P2 | "Venetoclax, a BCL-2 inhibitor, has shown promisein combination with hypomethylating agents (azacitidine or decitabine) or low-dose cytarabine, achievinga reinduction rate of approximately 40%...Eligible patients were randomized 1:1 to receive either CAV (cladribine 5 mg/m2/day, cytarabine20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21) or MEC (mitoxantrone8mg/m2 d1-5, etoposide 100mg/m2 d1-5, cytarabine 1g/m2 d1-5)...Our findings demonstrate that the CAV regimen represents an effective and well-tolerated salvagetherapy for R/R AML, particularly in venetoclax-naïve patients who achieved significantly superiorresponse rates. These promising results warrant further validation in larger prospective studies toconfirm the regimen's efficacy."

Clinical • P2 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Infectious Disease • Neutropenia • Pneumonia • Respiratory Diseases • Septic Shock

Improved overall survival in patients with advanced systemic mastocytosis treated with avapritinib versus real-world therapy based on mutation-adjusted risk score (MARS) stratification (ASH 2025) - P=N/A, P1, P2 | "This analysis builds on the earlier work, comparing OS betweenintermediate- and high-risk MARS pts treated with Ava (200 mg/day starting dose) in the PATHFINDER trialand those treated with BAT in real-world (RW) clinical practice.MethodsData from the PATHFINDER trial (median follow-up: 38.0 months) and a RW retrospective chart reviewstudy (NCT04695431) conducted at six global sites, were used to compare OS between pts treated with 1LAva vs 1L Mido, and 2L+ Ava vs 2L+ BAT, which was predominantly Mido and cladribine (Clad)...Common 2L+ BAT agents included Mido (47.5%), Clad (34.4%), and hydroxyurea (8.2%)...After adjustment, OSwas significantly improved in Ava vs BAT pts (HR [95% CI]: 0.31 [0.13, 0.74]; p=0.008).ConclusionsAmong the combined cohort of MARS intermediate- and high-risk AdvSM pts, avapritinib was associatedwith significantly improved OS compared to midostaurin in the 1L setting and BAT in the 2L+ setting,including in the SM-AHN subgroup. This..."

Clinical • Metastases • Real-world • Real-world evidence • Aggressive Systemic Mastocytosis • Hematological Disorders • Hematological Malignancies • Leukemia • Mast Cell Leukemia • Thrombocytopenia • ASXL1 • RUNX1 • SRSF2

Cladribine based salvage chemotherapy in AML patients with persistent or recurrent disease after venetoclax/HMA (ASH 2025) - "Therefore, to better distinguish outcomes in fit patients after Ven/HMA, and alsoto report outcomes after a cladribine based salvage regimen, which represents a common salvageapproach in R/R AML, we report the outcomes of this approach in pts treated at our institution.METHODSWe performed a retrospective study of pts with AML receiving either CLAG-M (cladribine 5mg/m2 D1-5,cytarabine 2G/m2 D1-5, G-CSF D1-5, mitoxantrone 10mg/m2 D1-3) or Cladribine-LDAC (cladribine5mg/m2 D1-5 cytarabine 40mg SQ D1-10) after receiving treatment with Ven/HMA. 7 pts were successfully bridged to allogeneic HCT,median OS among these pts was 8.8 mo.CONCLUSIONAmong fit AML pts receiving ven/HMA in a prior line, salvage chemotherapy with CLAG-M is reasonable,particularly if a pt requires bridging therapy for possible allogeneic HCT. Outcomes with CLAG-M salvageoverall remains suboptimal, necessitating the development of novel salvage therapies in patientspreviously exposed to ven/HMA."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • TP53

Homoharringtonine added to CLAG regimen improves outcome of pediatric Relapsed/Refractory AML: A multicenter prospective study (ASH 2025) - P4 | "All patients had received CHAG regimens for salvage chemotherapies asfollows: cladribine (5mg/m2/day, day 1-5), HHT (1mg/m2/day, day 1-14), cytarabine (10mg/m2, quaque 12hora, day 1-14), granulocyte colony-stimulating factor (200ug/m2/day, day1-14) (cycle 1). The most common nonhematologic toxicities were febrileneutropenia, mostly assessed as grade 3 to 4, and not life-threatening.ConclusionIn summary, this trial showed that CHAG regimen is safe and highly active in R/R AML children. The CHAGregimen may represent a highly promising bridging strategy to allo-HSCT in pediatric R/R AML."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Febrile Neutropenia • Neutropenia • Pediatrics • FLT3 • KMT2A • RUNX1 • RUNX1T1

Prospective evaluation of venetoclax combined with CLAG regimen in relapsed/refractory acute myeloid leukemia: A multicenter, randomized controlled, open-lable, phase II Trial (ASH 2025) - P4 | "CLAG (cladribine + cytarabine + G-CSF) based regimen is recommended for the salvage treatment ofrelapsed/refractory (RR) acute myeloid leukemia (AML). Adverse events including all grade and grade 3/4, also early mortality, occurredat similar frequencies in the two groups. In summary, our ongoing study demonstrated Ven combinedwith CLAG might significantly improve the outcome of the patients with RR-AML, with well toleration.Key words: CLAG, Venetoclax, salvage therapy, relapsed/refractory, acute myeloid leukemia"

Clinical • P2 data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • MECOM